Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Please scroll down for information on the following RFP:

  • Junior Investigator Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research

Request for Proposals (RFP)

Junior Investigator Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research

Date RFP Issued: January 15, 2021

Geographic Scope: all countries except the United States

Clinical Area: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Link to full RFP: Junior Investigator Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research

Application Due Date: March 22, 2021

Specific Area of Interest: Projects that will be considered will aim to improve the understanding of the epidemiology, basic science, early diagnosis and treatment of ATTR-CM through research focused in the following areas:

  • Epidemiologic evaluations for ATTR-CM
  • Approaches for the early identification and follow up of ATTR-CM patients
  • RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR-CM
  • Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)
  • Longitudinal evaluations of neurologic manifestations in patients with ATTR-CM including wild type
  • Mechanistic studies to advance the basic science of amyloid formation and deposition on the heart
  • Characteristics of ATTR-CM in post-organ transplant patients, including natural course of disease progression
  • European country specific early access program data collection

Refer to complete details in the full RFP documents. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).